Karuna therapeutics, inc. (KRTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
Cash flows from operating activities
Net loss

-8,658

-7,774

-9,038

-15,140

-12,005

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

1,634

981

1,642

6,841

3,104

Non-cash interest income

462

473

505

265

17

Non-cash interest income, net (Note 4)

-

0

0

0

11

Accretion of debt discount (Note 4)

-

0

0

522

423

Change in fair value of derivative liability (Note 4)

-

0

0

0

-135

Depreciation and amortization expense

21

21

15

12

10

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-132

986

606

1,486

-1,478

Right-of-use assets

-121

-

-

-

-

Accounts payable

24

389

-364

-332

585

Accrued expenses

-1,051

1,034

454

253

74

Deferred lease obligation

-

-12

-14

22

110

Operating lease liability

-102

-

-

-

-

Net cash used in operating activities

-8,341

-6,820

-8,416

-9,573

-6,114

Cash flows from investing activities
Purchases of short-term investments

70,350

-

-

-

-

Maturities of short-term investments

60,000

20,000

25,000

0

5,000

Acquisition of property and equipment

76

40

5

53

17

Net cash (used in) provided by investing activities

-10,426

-72,619

-42,178

-64,521

4,983

Cash flows from financing activities
Proceeds from issuance of convertible notes

-

0

0

1,564

1,564

Proceeds from exercise of stock options

517

-

-

-

-

Proceeds from exercise of warrant

-

0

0

0

58

Payment of deferred offering costs

-

0

1,210

1,102

97

Net cash provided by financing activities

517

234,224

94,243

314

76,502

Net increase in cash, cash equivalents and restricted cash

-18,250

154,785

43,649

-73,780

75,371

Supplemental disclosures of cash flows information
Lease liabilities arising from obtaining right-of-use assets

2,851

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

121

-

-

-

-

Deferred offering costs included in accrued expenses

34

-

-

304

529

Conversion of convertible notes, accrued interest and discount upon conversion to preferred stock

-

0

0

2,086

5,016

Series B Redeemable Convertible Preferred Stock
Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance costs

-

0

0

-152

74,977